TISIDB

Summary
Symbol	GRIK4
Name	glutamate receptor, ionotropic, kainate 4
Aliases	GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location	11q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane; Multi-pass membrane protein. Cell junction, synapse, postsynaptic cell membrane; Multi-pass membrane protein.
Domain	PF01094 Receptor family ligand binding region PF00060 Ligand-gated ion channel PF10613 Ligated ion channel L-glutamate- and glycine-binding site
Function	Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists.

> Gene Ontology [ TOP ]
Biological Process	GO:0007215 glutamate receptor signaling pathway GO:0035235 ionotropic glutamate receptor signaling pathway
Molecular Function	GO:0004970 ionotropic glutamate receptor activity GO:0005216 ion channel activity GO:0005230 extracellular ligand-gated ion channel activity GO:0005231 excitatory extracellular ligand-gated ion channel activity GO:0005234 extracellular-glutamate-gated ion channel activity GO:0008066 glutamate receptor activity GO:0015267 channel activity GO:0015276 ligand-gated ion channel activity GO:0015277 kainate selective glutamate receptor activity GO:0022803 passive transmembrane transporter activity GO:0022824 transmitter-gated ion channel activity GO:0022834 ligand-gated channel activity GO:0022835 transmitter-gated channel activity GO:0022836 gated channel activity GO:0022838 substrate-specific channel activity GO:0030594 neurotransmitter receptor activity
Cellular Component	GO:0008328 ionotropic glutamate receptor complex GO:0032983 kainate selective glutamate receptor complex GO:0034702 ion channel complex GO:0042734 presynaptic membrane GO:0043235 receptor complex GO:0045211 postsynaptic membrane GO:0097060 synaptic membrane GO:0098793 presynapse GO:0098794 postsynapse GO:0098802 plasma membrane receptor complex GO:0098878 neurotransmitter receptor complex GO:1902495 transmembrane transporter complex GO:1990351 transporter complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04080 Neuroactive ligand-receptor interaction hsa04724 Glutamatergic synapse
Reactome	R-HSA-451308: Activation of Ca-permeable Kainate Receptor R-HSA-451326: Activation of Kainate Receptors upon glutamate binding R-HSA-451306: Ionotropic activity of Kainate Receptors R-HSA-112316: Neuronal System R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell R-HSA-112315: Transmission across Chemical Synapses

Summary
Symbol	GRIK4
Name	glutamate receptor, ionotropic, kainate 4
Aliases	GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location	11q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between GRIK4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	GRIK4
Name	glutamate receptor, ionotropic, kainate 4
Aliases	GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location	11q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of GRIK4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	GRIK4
Name	glutamate receptor, ionotropic, kainate 4
Aliases	GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location	11q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of GRIK4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.187	0.392
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.488	0.375
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.027	0.943
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.03	0.94
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.119	0.918
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.217	0.873
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.43	0.533
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.341	0.775
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-1.164	0.402
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.001	0.999
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.473	0.572
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.674	0.00219

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of GRIK4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	1.4	9.7	0.0589
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	1.7	9.4	0.0895
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	11.8	-7	0.577
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	18.2	-10.5	0.576
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	12.5	9.7	0.602
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	22.2	-2.2	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	GRIK4
Name	glutamate receptor, ionotropic, kainate 4
Aliases	GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location	11q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GRIK4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	GRIK4
Name	glutamate receptor, ionotropic, kainate 4
Aliases	GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location	11q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GRIK4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GRIK4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	GRIK4
Name	glutamate receptor, ionotropic, kainate 4
Aliases	GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location	11q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GRIK4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	GRIK4
Name	glutamate receptor, ionotropic, kainate 4
Aliases	GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location	11q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of GRIK4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	GRIK4
Name	glutamate receptor, ionotropic, kainate 4
Aliases	GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location	11q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between GRIK4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	GRIK4
Name	glutamate receptor, ionotropic, kainate 4
Aliases	GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location	11q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting GRIK4 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting GRIK4.

ID	Name	Drug Type	Targets	#Targets
DB00142	Glutamic Acid	Small Molecule	AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, CPQ, DNPEP ......	69

Browse GRIK4